Literature DB >> 8454345

Restricted ability of group B streptococcal C5a-ase to inactivate C5a prepared from different animal species.

J F Bohnsack1, J K Chang, H R Hill.   

Abstract

Most strains of group B streptococci (GBS) elaborate a cell surface-associated enzyme that rapidly inactivates the human complement-derived chemoattractants C5a and C5adesarg by cleaving the His-Lys bond at positions 67 and 68 in the C5a molecule. We have suggested that rapid inactivation of C5a and C5adesarg by this enzyme, called C5a-ase, can hinder the inflammatory response at sites of GBS infection. We tested the ability of GBS C5a-ase to inactivate C5a preparations from various animal species to determine the proper species for studying the role of GBS C5a-ase in the pathogenesis of GBS infections. Exposure of C5a preparations from humans, monkeys, and cows to GBS caused inhibition of C5a functional activity as measured by the ability of C5a to stimulate human polymorphonuclear leukocyte (PMN) adherence and human PMN chemotaxis. Bovine PMN chemotaxis to bovine C5a was also abolished after exposure of bovine C5a to GBS. In contrast, mouse, rat, guinea pig, rabbit, pig, and sheep C5a preparations retained full functional activity after exposure to GBS as measured by chemotaxis of human PMNs, PMNs from the same animal species, or both. These data suggest that there are structural differences between C5a proteins from different species which alter their susceptibility to GBS C5a-ase and indicate that most commonly used animal models of human GBS infection are inadequate for detection of a contribution of GBS C5a-ase to GBS virulence.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8454345      PMCID: PMC281380          DOI: 10.1128/iai.61.4.1421-1426.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis.

Authors:  K W Mollison; W Mandecki; E R Zuiderweg; L Fayer; T A Fey; R A Krause; R G Conway; L Miller; R P Edalji; M A Shallcross
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

2.  Bacterial evasion of the antibody response: human IgG antibodies neutralize soluble but not bacteria-associated group B streptococcal C5a-ase.

Authors:  J F Bohnsack; X N Zhou; J N Gustin; C E Rubens; C J Parker; H R Hill
Journal:  J Infect Dis       Date:  1992-02       Impact factor: 5.226

3.  Purification of the proteinase from group B streptococci that inactivates human C5a.

Authors:  J F Bohnsack; X N Zhou; P A Williams; P P Cleary; C J Parker; H R Hill
Journal:  Biochim Biophys Acta       Date:  1991-08-30

4.  Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus.

Authors:  J F Bohnsack; K W Mollison; A M Buko; J C Ashworth; H R Hill
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

5.  Group B streptococci inhibit the chemotactic activity of the fifth component of complement.

Authors:  H R Hill; J F Bohnsack; E Z Morris; N H Augustine; C J Parker; P P Cleary; J T Wu
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

6.  Isolation of leukocytes from bovine peripheral blood.

Authors:  G P Carlson; J J Kaneko
Journal:  Proc Soc Exp Biol Med       Date:  1973-03

7.  Group B streptococcus induces tumor necrosis factor in neonatal piglets. Effect of the tumor necrosis factor inhibitor pentoxifylline on hemodynamics and gas exchange.

Authors:  R L Gibson; G J Redding; W R Henderson; W E Truog
Journal:  Am Rev Respir Dis       Date:  1991-03

8.  Role of pulmonary phagocytes in host defense against group B streptococci in preterm versus term rabbit lung.

Authors:  M P Sherman; J T Johnson; R Rothlein; B J Hughes; C W Smith; D C Anderson
Journal:  J Infect Dis       Date:  1992-10       Impact factor: 5.226

9.  Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci.

Authors:  M B Marques; D L Kasper; M K Pangburn; M R Wessels
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

10.  Pathophysiology and histopathology of group B streptococcal sepsis in Macaca nemestrina primates induced after intraamniotic inoculation: evidence for bacterial cellular invasion.

Authors:  C E Rubens; H V Raff; J C Jackson; E Y Chi; J T Bielitzki; S L Hillier
Journal:  J Infect Dis       Date:  1991-08       Impact factor: 5.226

View more
  18 in total

1.  Conservation of the C5a peptidase genes in group A and B streptococci.

Authors:  I Chmouryguina; A Suvorov; P Ferrieri; P P Cleary
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  A streptococcal protease that degrades CXC chemokines and impairs bacterial clearance from infected tissues.

Authors:  Carlos Hidalgo-Grass; Inbal Mishalian; Mary Dan-Goor; Ilia Belotserkovsky; Yoni Eran; Victor Nizet; Amnon Peled; Emanuel Hanski
Journal:  EMBO J       Date:  2006-09-14       Impact factor: 11.598

3.  Modulation of neutrophil chemokine receptors by Staphylococcus aureus supernate.

Authors:  K E Veldkamp; H C Heezius; J Verhoef; J A van Strijp; K P van Kessel
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Role of C5a-ase in group B streptococcal resistance to opsonophagocytic killing.

Authors:  S Takahashi; Y Nagano; N Nagano; O Hayashi; F Taguchi; Y Okuwaki
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

Review 5.  Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.

Authors:  Gunnar Lindahl; Margaretha Stålhammar-Carlemalm; Thomas Areschoug
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

6.  The SrtA Sortase of Streptococcus agalactiae is required for cell wall anchoring of proteins containing the LPXTG motif, for adhesion to epithelial cells, and for colonization of the mouse intestine.

Authors:  Lila Lalioui; Elisabeth Pellegrini; Shaynoor Dramsi; Marina Baptista; Nadege Bourgeois; Florence Doucet-Populaire; Christophe Rusniok; Mohamed Zouine; Philippe Glaser; Frank Kunst; Claire Poyart; Patrick Trieu-Cuot
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

7.  Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice.

Authors:  Qi Cheng; Steven Debol; Hong Lam; Ron Eby; Lorri Edwards; Yury Matsuka; Stephen B Olmsted; P Patrick Cleary
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

8.  Molecular characterization of the cfb gene encoding group B streptococcal CAMP-factor.

Authors:  A Podbielski; O Blankenstein; R Lütticken
Journal:  Med Microbiol Immunol       Date:  1994-11       Impact factor: 3.402

9.  C5a peptidase alters clearance and trafficking of group A streptococci by infected mice.

Authors:  Y Ji; L McLandsborough; A Kondagunta; P P Cleary
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

10.  Human serum induces streptococcal c5a peptidase expression.

Authors:  Ute Gleich-Theurer; Simone Aymanns; Gregor Haas; Stefanie Mauerer; Julia Vogt; Barbara Spellerberg
Journal:  Infect Immun       Date:  2009-06-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.